Noxopharm Limited (ASX:NOX)

Market Cap	20.58M -20.9%
Revenue (ttm)	1.43M -49.4%
Net Income	-4.46M
EPS	-0.02
Shares Out	307.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,498
Open	0.0650
Previous Close	0.0670
Day's Range	0.0650 - 0.0650
52-Week Range	0.0510 - 0.1100
Beta	0.01
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 27, 2026

About Noxopharm

Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions. The company als...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NOX

Financial Performance

In fiscal year 2026, Noxopharm's revenue was 1.43 million, a decrease of -49.40% compared to the previous year's 2.82 million. Losses were -4.46 million, -8.77% less than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 18, 2026

Data Sources Report a data error